Elan reports net profit of $68.2m in first quarter boosted by Tysabri sales
Apr 20th, 2011 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Elan, the Irish pharmaceutical company, today reported a net profit of $68.2m for the first quarter of this year, boosted by robust sales of its multiple sclerosis drug Tysabri and a 10% cut in its day-to-day costs.